BESUNYEN (00926) has announced its interim results for the six months ended June 30, 2026, reporting a net profit of RMB 15.066 million, a 21.48% increase year-on-year.

The company achieved revenue of RMB 305 million, up 17.74% compared to the same period last year, with basic earnings per share standing at RMB 0.12.

The revenue growth was primarily driven by a sharp 43.8% increase in sales from its four-tea product line, though this was partially offset by a decline in sales volumes of other pharmaceutical products and health supplements, the company stated in its filing.